市場調査レポート - 138803

外傷性脳損傷:研究開発パイプライン分析と市場見通し

Traumatic Brain Injury - R&D Pipeline Assessment and Market Prospects

発行 Arrowhead Publishers
出版日 ページ情報 英文
価格
外傷性脳損傷:研究開発パイプライン分析と市場見通し Traumatic Brain Injury - R&D Pipeline Assessment and Market Prospects
出版日: 2010年11月19日 ページ情報: 英文
概要

当レポートでは、外傷性脳損傷に関する研究開発動向について包括的に分析し、現状と課題、および機会とともに、候補薬の商品化見通し、新たな動向などをまとめ、概略下記の構成でお届けいたします。

第1章 調査目的

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 外傷性脳損傷とバイオ医薬品業界

  • 特許保護の失効
  • 厳しくなる償還基準

第5章 外傷性脳損傷の背景

  • 定義
  • 類型論
  • 原因
  • 症状
  • 予後
  • 統計と動向
  • 治療
  • 脳損傷につづく一般的症状

第6章 外傷性脳損傷の商業的重要性

  • 治療のアンメットニーズ
  • 外傷性脳損傷の視認性拡大
  • 費用検証:外傷性脳損傷患者の治療

第7章 潜在的市場概要

  • 人口統計および病因学的考察
  • クオリティオブライフ:より人道的なアプローチ
  • 健康への意識拡大
  • 世界の主な外傷性脳損傷市場
  • 世界の概要

第8章 外傷性脳損傷研究パイプライン

  • 概要
  • 治験デザイン
  • 外傷性脳損傷パイプラインにある候補薬
  • 早期段階の研究
  • その他の研究分野
  • 失敗した研究

第9章 外傷性脳損傷:財務予想

  • 外傷性脳損傷R&Dの課題と機会
  • 外傷性脳損傷の財務予想

第10章 外傷性脳損傷研究における将来動向

  • 医療用画像装置
  • 業界の提携:大小提携
  • 性別、年齢、関連考察
  • 心理的、社会的問題
  • 法規制
  • 複雑な問題
  • 新たな方向性

付録

図表

目次

Some sources estimate that TBI is ten times as prevalent as spinal cord injury and on an annual basis, at least 150 people per 100,000 population are treated in hospitals for TBI. In the United States, statistics provided by the National Centers for Disease Control (CDC) report that - on an annual basis - some one million people are impacted by TBI.

As a consequence of increased military engagement, more soldiers are returning from combat theaters with TBIs. It has been estimated that up to 83 percent of soldiers returning from Afghanistan and Iraq exhibit a variety of brain injury symptoms. To add to this picture, increased attention is being paid to athletes affected by TBI and the link to early-onset dementia.

Currently, no effective TBI therapy exists, with patients treated through a combination of surgery, rehabilitation and pharmacological agents managing post-trauma conditions such as depression. Consequently, the considerable target population leads Arrowhead Publishers to estimate that the global market value for TBI therapy is in the region of US$1-2 billion, with the majority of this accounted for by potential demand across Europe and in the United States.

Traumatic Brain Injury: R&D Pipeline Assessment and Market Prospects takes a closer look at TBI and its future treatment prospects. It provides a thorough examination of its causes, symptoms, prognosis, treatment, epidemiology and unmet clinical need. In addition, it provides the reader with an overview of key potential markets for TBI therapeutics and assesses various therapies currently in development for TBI. Future trends in TBI research are also discusses at length. Finally, financial forecasts for the TBI therapeutic market are provided along with an analysis of the challenges and opportunities facing developers of TBI therapies.

What questions does this report answer?

  • What are the major issues involved in the research and development of more effective TBI therapeutics?
  • What is the current status of the TBI pipeline?
  • What types of TBI therapeutics are currently in research and development?
  • What is the anticipated market for potential TBI treatments?
  • Which TBI pipeline candidates are having the best clinical trial results?

Highlights of this report include:

  • A discussion of the problems associated with the current treatment options for TBI
  • Focused analysis of the global prevalence of TBI
  • Identification of the potential key markets for TBI product candidates
  • Valuable input from leaders in TBI research
  • Discussion of the wider social and economic considerations leading to increased interest in TBI

Reasons to buy this report:

  • It provides a comprehensive assessment of the challenges and opportunities for those engaged in the field of TBI R&D
  • Discusses key candidates and their commercialization prospects
  • Describes emerging trends in R&D

Unique features of this report include:

  • Critical assessment of likely success of leading clinical candidates
  • Forecasts of the global and US markets for TBI therapies
  • Thorough discussion of important areas of research and development in TBI

Table of Contents

1. REPORT OBJECTIVES

2. METHODOLOGY

3. EXECUTIVE SUMMARY

4. TBI AND THE BIOPHARMACEUTICAL INDUSTRY

  • 4.1 LOSS OF PATENT PROTECTION
  • 4.2 TIGHTER REIMBURSEMENT CRITERIA

5. TRAUMATIC BRAIN INJURY (TBI) BACKGROUND

  • 5.1 DEFINITIONS
  • 5.2 TYPOLOGIES
  • 5.3 CAUSES
  • 5.4 SYMPTOMS
  • 5.5 PROGNOSIS
  • 5.6 STATISTICS AND TRENDS
  • 5.7 TREATMENT
  • 5.8 COMMON CONDITIONS FOLLOWING BRAIN INJURIES

6. COMMERCIAL SIGNIFICANCE OF TBI

  • 6.1 THE UNMET TREATMENT NEED
  • 6.2 INCREASED VISIBILITY OF TBI
  • 6.3 COST-CONSIDERATIONS: CARING FOR TBI PATIENTS

7. OVERVIEW OF KEY POTENTIAL MARKETS

  • 7.1 DEMOGRAPHIC AND ETIOLOGICAL CONSIDERATIONS
  • 7.2 QUALITY OF LIFE: A MORE HUMANE APPROACH
  • 7.3 INCREASED HEALTH AWARENESS
  • 7.4 LEADING (POTENTIAL) GLOBAL TBI MARKETS
    • 7.4.1 UNITED STATES
    • 7.4.2 EUROPEAN UNION (EU)
    • 7.4.3 JAPAN
  • 7.5 GLOBAL OVERVIEW

8. TRAUMATIC BRAIN INJURY (TBI) RESEARCH PIPELINE

  • 8.1 OVERVIEW
  • 8.2 CLINICAL TRIAL DESIGNS
  • 8.3 KEY PRODUCT CANDIDATES IN THE TBI PIPELINE
    • 8.3.1 NUVIGIL (ARMODAFINIL)/CEPHALON
      • 8.3.1.1 CLINICAL DEVELOPMENT
      • 8.3.1.2 PRODUCT ASSESSMENT
    • 8.3.2 BHR-100 (PROGESTERONE)/BHR PHARMA
      • 8.3.2.1 CLINICAL DEVELOPMENT
      • 8.3.2.2 PRODUCT ASSESSMENT
    • 8.3.3 NH001 (APOMORPHINE)/NEUROHEALING PHARMACEUTICALS
      • 8.3.3.1 CLINICAL DEVELOPMENT
      • 8.3.3.2 PRODUCT ASSESSMENT
    • 8.3.4 NNZ-2566/NEUREN PHARMACEUTICALS
      • 8.3.4.1 CLINICAL DEVELOPMENT
      • 8.3.4.2 PRODUCT ASSESSMENT
    • 8.3.5 VAS-203/VASOPHARM
      • 8.3.5.1 CLINICAL DEVELOPMENT
      • 8.3.5.2 PRODUCT ASSESSMENT
    • 8.3.6 OXYCYTE/OXYGEN BIOTHERAPEUTICS
      • 8.3.6.1 CLINICAL DEVELOPMENT
      • 8.3.6.2 PRODUCT ASSESSMENT
    • 8.3.7 ZOLPIDEM/REGEN THERAPEUTICS
      • 8.3.7.1 CLINICAL DEVELOPMENT
      • 8.3.7.2 PRODUCT ASSESSMENT
    • 8.3.8 ATORVASTATIN/BAYLOR COLLEGE OF MEDICINE
      • 8.3.8.1 CLINICAL DEVELOPMENT
      • 8.3.8.2 PRODUCT ASSESSMENT
    • 8.3.9 KN38-7271/KEYNEUROTEK PHARMACEUTICALS
      • 8.3.9.1 CLINICAL DEVELOPMENT
      • 8.3.9.2 PRODUCT ASSESSMENT
    • 8.3.10 NTX428/STEM CELL THERAPEUTICS (SCT)
      • 8.3.10.1 CLINICAL DEVELOPMENT
      • 8.3.10.2 PRODUCT ASSESSMENT
  • 8.4 EARLY STAGE RESEARCH
    • 8.4.1 TT-301/TRANSITION THERAPEUTICS
    • 8.4.2 HUPERZINE A/CHILDREN' S HOSPITAL BOSTON (CHB)
    • 8.4.3 PEPTIDOMIMETICS/ARDANE
    • 8.4.4 REMYELATION/ACORDA
    • 8.4.5 MULTISTEM/ATHERSYS
  • 8.5 OTHER AREAS OF RESEARCH
    • 8.5.1 STEM CELL TREATMENT
    • 8.5.2 HYPERBARIC OXYGEN (HBO) CHAMBER
    • 8.5.3 RIBAVIRIN
  • 8.6 FAILED RESEARCH
    • 8.6.1 SALINE SOLUTIONS
    • 8.6.2 SLV334

9. THE TBI MARKET: FINANCIAL FORECASTS

  • 9.1 CHALLENGES AND OPPORTUNITIES IN TBI R&D
  • 9.2 FINANCIAL FORECASTS FOR THE TRAUMATIC BRAIN INJURY MARKET

10. FUTURE TRENDS IN TBI RESEARCH

  • 10.1 MEDICAL IMAGING: THE HELPING HAND
  • 10.2 INDUSTRY COLLABORATION: THE BIG AND THE SMALL
  • 10.3 GENDER, AGE AND RELATED CONSIDERATIONS
  • 10.4 PSYCHOLOGICAL AND SOCIAL ISSUES
  • 10.5 REGULATORY ISSUES
  • 10.6 COMPLEX PROBLEM: COMPLEX SOLUTION
  • 10.7 NEW DIRECTIONS

APPENDIX I: KEY COMPANIES AND INSTITUTIONS INVOLVED IN TRAUMATIC BRAIN INJURY RESEARCH

TABLES

  • TABLE 4.1 PATENT EXPIRATION DATES FOR SELECTED PRODUCTS
  • TABLE 5.1 THE GLASGOW COMA SCALE
  • TABLE 5.2 THE RANCHOS LOS AMIGOS SCALE
  • TABLE 5.3 TOOLS FOR DIAGNOSING THE SEVERITY OF TRAUMATIC BRAIN INJURY
  • TABLE 5.4 THE GLASGOW OUTCOME SCALE
  • TABLE 5.5 THE DISABILITY RATING SCALE
  • TABLE 5.6 THE DISABILITY RATING SCALE - INTERPRETATION OF SCORES
  • TABLE 5.7 INCIDENCE OF RECOVERY OF CONSCIOUSNESS AND FUNCTION IN ADULTS AND CHILDREN IN A PERSISTENT VEGETATIVE STATE (PVS) AFTER TRAUMATIC OR NONTRAUMATIC BRAIN INJURY
  • TABLE 5.8 COMMON CONSEQUENCES OF TRAUMATIC BRAIN INJURY
  • TABLE 7.1 SPORTS-RELATED HEAD INJURIES BY TYPE OF SPORT (2007)
  • TABLE 7.2 TBI MORTALITY RATE BY 100,000 POPULATION IN SELECT COUNTRIES/REGIONS
  • TABLE 7.3 BURDEN OF NEUROLOGICAL DISORDERS, IN YEARS OF HEALTHY LIFE LOST TO DISABILITY (YLDS), AS PERCENTAGE OF TOTAL, BY CAUSE - PROJECTIONS FOR 2005, 2015 AND 2030
  • TABLE 8.1 DIFFICULTIES FACING DESIGNERS OF TBI CLINICAL TRIALS
  • TABLE 8.2 OVERVIEW OF TRAUMATIC BRAIN INJURY PIPELINE
  • TABLE 9.1 KEY CHALLENGES AND OPPORTUNITIES IN TBI R&D
  • TABLE 9.2 ESTIMATES OF PEAK SALES AND POTENTIAL LAUNCH DATES FOR SELECT TBI PIPELINE CANDIDATES

GRAPHS

  • GRAPH 5.1 TRAUMATIC BRAIN INJURY CASES BY CAUSE
  • GRAPH 5.2 TRAUMATIC BRAIN INJURY CASES BY SEVERITY
  • GRAPH 6.1 ESTIMATE OF DIRECT AND INDIRECT COSTS OF TRAUMATIC BRAIN INJURY AS PERCENTAGE OF TOTAL GLOBAL COSTS PER ANNUM
  • GRAPH 7.1 NUMBER OF ROAD ACCIDENTS, 1994-2004
  • GRAPH 7.2 THE NUMBER OF PERSONS KILLED IN ROAD ACCIDENTS, 1994-2004
  • GRAPH 7.3 THE NUMBER OF PERSONS INJURED IN ROAD ACCIDENTS, 1994-2004
  • GRAPH 7.4 CASES OF TRAUMATIC BRAIN INJURY BY CAUSE IN THE UNITED STATES
  • GRAPH 7.5 ETIOLOGY OF TRAUMATIC BRAIN INJURIES IN THE UNITED STATES
  • GRAPH 7.6 TOP TEN CAUSES OF HEAD INJURIES IN CHILDREN AGED 14 AND YOUNGER
  • GRAPH 7.7 EXTERNAL CAUSES OF TRAUMATIC BRAIN INJURY IN SELECTED GEOGRAPHICAL AREAS
  • GRAPH 9.1 FORECAST VALUE OF THE TRAUMATIC BRAIN INJURY MARKET IN THE UNITED STATES 2015-2020

FIGURES

  • FIGURE 8.1 THE NEURON - THE BRAIN CELL
  • FIGURE 8.2 THE DIAGRAM OF THE BRAIN
  • FIGURE 8.3 EFFECTS OF ICV INJECTION OF RIBAVIRIN
Back to Top